Maintenance. We are currently updating the site. Please check back shortly

Thomson Reuters Foundation

Inform - Connect - Empower

China adjusts pricing policy for cheaper drugs

Source: Reuters - Fri, 9 May 2014 04:21 GMT
Author: Reuters
hum-dis
Tweet Recommend Google + LinkedIn Email Print
Leave us a comment

SHANGHAI, May 9 (Reuters) - China has adjusted its policy on pricing cheaper drugs sold in the country, allowing drugmakers more leeway in deciding how much to charge for their treatments in the face of rising costs.

Under the new policy announced by the price regulator, over 500 drugs considered to be essential for public health will now be officially classified as "low-priced" drugs and sold for standard rates. Prices will be capped at 3 yuan ($0.48) per daily dosage for Western drugs, and 5 yuan for traditional Chinese medicine.

Previously, China set individual price caps for over 2,000 drugs covered by national health insurance.

"Compared with high-priced drugs, the profitability of cheap medicine is low, which limits the (drugmakers') ability to absorb rising costs," the National Development and Reform Commission (NDRC) said in a statement posted on its website on Thursday.

As a result, there had been shortages of low-priced drugs after drugmakers had become less willing to produce them, it said.

Last year, the NDRC launched an investigation over costs and pricing at Chinese and foreign pharmaceuticals firms. Industry executives have said this was a part of Beijing's move to analyse the difference in prices of imported products sold by foreign firms in China compared with those in other markets.

The NDRC has yet to announce the result of this investigation.

The Shanghai stock exchange's sub-index of healthcare firms was down 0.2 percent at midday on Friday. Broader indices were down around 0.3 percent.

($1 = 6.2280 Chinese Yuan) (Reporting by Kazunori Takada; Editing by Kenneth Maxwell)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of the Thomson Reuters Foundation. For more information see our Acceptable Use Policy.

comments powered by Disqus